. 2020 Apr 21;64(5):e02375-19. doi: 10.1128/AAC.02375-19

TABLE 1.

Activities of KBP-7072 and comparators against 531 recent geographically diverse Acinetobacter baumannii isolates

Antimicrobial agent (no. of isolates tested)	MIC range (mg/liter)	MIC_50/90 (mg/liter)	CLSI^a			EUCAST^a
Antimicrobial agent (no. of isolates tested)	MIC range (mg/liter)	MIC_50/90 (mg/liter)	% S	% I	% R	% S	% I	% R
KBP-7072 (531)	≤0.015 to 4	0.25/1	99.2^b
Tigecycline (531)	0.06 to 16	1/4	79.5^c	18.2	2.3
Doxycycline (453)	≤0.06 to >8	1/>8	67.3	2.0	30.7
Minocycline (454)	≤0.03 to >8	1/>8	73.8	6.8	19.4
Tetracycline (457)	0.5 to >8	>8/>8	37.2	7.2	55.6
Ceftazidime (531)	0.5 to >16	>16/>16	40.3	6.0	53.7
Colistin (528)	≤0.5 to >8	≤0.5/1	92.8		7.2	92.8		7.2
Gentamicin (531)	≤2 to >8	8/>8	48.2	4.9	46.9	48.2		51.8
Levofloxacin (531)	0.03 to >4	>4/>4	39.5	2.8	57.6	37.9	1.3	60.8
Meropenem (531)	0.12 to >8	>8/>8	42.0	0.8	57.3	42.0	2.3	55.7
Piperacillin-tazobactam (520)	≤0.06 to >128	>64/>64	33.3	5.2	61.5

Criteria according to CLSI (2019) and EUCAST (2019) guidelines (22, 24).

Percent inhibited at ≤2 mg/liter for comparison purposes only.

Tigecycline FDA breakpoint criteria for Enterobacteriaceae applied to A. baumannii isolates for comparison purposes only (25).